Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Pediatric Patients With Moderate to Severe Crohn's Disease
Phase of Trial: Phase III
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 09 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 21 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 24 Apr 2012 New trial record